StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO)

Equities researchers at StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report issued on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.

Aptose Biosciences Stock Performance

Shares of NASDAQ APTO opened at $0.40 on Tuesday. Aptose Biosciences has a 52 week low of $0.33 and a 52 week high of $3.32. The stock has a market capitalization of $7.23 million, a P/E ratio of -0.09 and a beta of 1.26. The stock’s fifty day moving average is $0.38 and its 200 day moving average is $0.67.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.15.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp raised its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the period. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. 26.62% of the stock is owned by hedge funds and other institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.